I leverage the capacity to search for targeted people at companies of interest. ![]() I use LinkedIn as a refined yellow pages. the career version of premium has access to a job seekers group) Overcome the limitations of commercial use restrictions (when LinkedIn only shows you so many search results).Improve my chances of being seen (Premium logo by my name).My decision to purchase premium services revolved around the following: Your decision might be different, so take advantage of any Free trials (if you get it free, go for Sales Navigator). As a job seeking professional, I never paid for premium services, nor do I promote its usage to job seekers. FYI - I've used both premium and free services (including LinkedIn Business and Sales Navigator). I've been watching the paid service evolution since I first established an account in 2004. LinkedIn has a habit of providing great new features for free, then pulling them back behind a paywall or paid service. The most obvious of revenue streams is Premium services - something that LinkedIn encourages you to purchase at every turn. It is a really valuable tool and ought to obtain revenue. As part of Microsoft, executives are compensated by performance based on key metrics for LinkedIn. Preliminary results indicate that retatrutide has the potential to induce weight loss more than any drug currently on the market.As a long-time LinkedIn user, it's not hard to see how LinkedIn is generating revenue. ![]() Until then, treatments such as Eli Lily’s retatrutide are needed more than ever. This relies on the development of a long-term strategy by governments worldwide to reform approaches to nutrition, exercise, and health. However, the obesity crisis continues to expand regardless of the consistent clinical research that has shown the importance of prevention. This indicates that the severity of the issue is not being taken for granted within the industry. It has also racked up astronomical costs in the US as medical expenses for the obese are 30%–40% higher.ĭata obtained from GlobalData’s Trials Intelligence platform shows that the number of clinical trials for obesity has increased in proportion to the prevalence of the disease (Figure 1, above). The obesity crisis is threatening to cripple the National Health Service (NHS) in the UK. The World Obesity Federation’s Atlas 2023 reiterated the severity of the prevalence as they estimated that 51% of the world, which is more than four billion people, will be obese by 2035 at the current trajectory of the disease. According to the World Health Organization (WHO) worldwide, more than one billion people are obese. Obesity is a severe public health problem that leads to several co-morbidities such as type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, and non-alcoholic fatty liver disease. The significant increase in the prevalence of obesity over the last few decades has resulted in the disease reaching pandemic proportions. Retatrutide suppresses appetite by binding to the GLP-1 receptors responsible for controlling hunger and satiety this allows people to feel fuller for longer, which regulates blood sugar levels and induces weight loss. ![]() This comes on the heels of the company’s successful Phase II trial, which saw retatrutide achieve a mean weight reduction of up to 17.5% at 24 weeks and 24.4% at 48 weeks in obese/overweight adults. The Phase III trial for Eli Lily’s pipeline drug retatrutide for the treatment of type 2 diabetes, non-alcoholic fatty liver disease, and obesity began on 28 August 2023. Source: GlobalData, Pharma Intelligence Center (Accessed August 2023).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |